A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Ae Jeong | - |
dc.contributor.author | Choi, Won-Mook | - |
dc.contributor.author | Kim, Hyo Jeong | - |
dc.contributor.author | Choi, So Hyun | - |
dc.contributor.author | Han, Seungbong | - |
dc.contributor.author | Ko, Min Jung | - |
dc.contributor.author | Lim, Young-Suk | - |
dc.date.accessioned | 2022-03-03T07:41:41Z | - |
dc.date.available | 2022-03-03T07:41:41Z | - |
dc.date.created | 2022-03-02 | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137597 | - |
dc.description.abstract | Many patients with chronic hepatitis B do not receive adequate follow-up. This study aimed to develop a risk score to predict clinical events in patients with chronic hepatitis B virus (HBV) infection at the population level for identifying patients at high risk to warrant regular follow-up. This study analysed population-based data from the nationwide claims database of South Korea obtained between 2005 and 2015. We identified 507,239 non-cirrhotic patients with chronic HBV infection who are not under antiviral treatment. A risk score for predicting clinical events (hepatocellular carcinoma, death or liver transplantation) was developed based on multivariable Cox proportional hazard model in a development cohort (n = 401,745) and validated in a validation cohort (n = 105,494). The cumulative incidence rates of clinical events at 5 years were 2.56% and 2.44% in the development and validation cohorts, respectively. Clinical events in asymptomatic patients with chronic HBV infection (CAP-B) score ranging from 0 to 7.5 points based on age, sex, socioeconomic status, chronic hepatitis C co-infection, diabetes mellitus, statin or antiplatelet exposure, smoking, alcohol consumption, alanine aminotransferase and gamma-glutamyltransferase had good discriminatory accuracy in both the development and validation cohorts (c-indices for 3-, 5- and 10-year risk prediction: all 0.786). The predicted and observed probabilities of clinical events were calibrated in both cohorts. A score of >3.5 points identified subjects at distinctly high risk. The CAP-B score using easily accessible variables can predict clinical events and may allow selection of patients with chronic HBV infection for priority of regular follow-up. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | HEPATOCELLULAR-CARCINOMA RISK | - |
dc.subject | POPULATION | - |
dc.subject | MODEL | - |
dc.subject | COMORBIDITIES | - |
dc.subject | VALIDATION | - |
dc.subject | CIRRHOSIS | - |
dc.title | A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Seungbong | - |
dc.identifier.doi | 10.1111/jvh.13631 | - |
dc.identifier.scopusid | 2-s2.0-85119187589 | - |
dc.identifier.wosid | 000719903800001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, v.29, no.2, pp.115 - 123 | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.citation.title | JOURNAL OF VIRAL HEPATITIS | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 115 | - |
dc.citation.endPage | 123 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA RISK | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordPlus | COMORBIDITIES | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordAuthor | death | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | liver transplantation | - |
dc.subject.keywordAuthor | national health insurance database | - |
dc.subject.keywordAuthor | risk prediction | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.